{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:27:59Z","timestamp":1792211279122,"version":"4.4.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["PPRPGM-Nov20\\100002"],"award-info":[{"award-number":["PPRPGM-Nov20\\100002"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["PPRPGM-Nov20\\100002"],"award-info":[{"award-number":["PPRPGM-Nov20\\100002"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["PPRPGM-Nov20\\100002"],"award-info":[{"award-number":["PPRPGM-Nov20\\100002"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["SEBCD3-2024\/100001"],"award-info":[{"award-number":["SEBCD3-2024\/100001"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009794","name":"Breast Cancer Now","doi-asserted-by":"publisher","award":["BGS-Q4-Y1 to Y5"],"award-info":[{"award-number":["BGS-Q4-Y1 to Y5"]}],"id":[{"id":"10.13039\/100009794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009794","name":"Breast Cancer Now","doi-asserted-by":"publisher","award":["BGS-Q4-Y1 to Y5"],"award-info":[{"award-number":["BGS-Q4-Y1 to Y5"]}],"id":[{"id":"10.13039\/100009794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009794","name":"Breast Cancer Now","doi-asserted-by":"publisher","award":["BGS-Q4-Y1 to Y5"],"award-info":[{"award-number":["BGS-Q4-Y1 to Y5"]}],"id":[{"id":"10.13039\/100009794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,11,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The National Institute for Health and Care Excellence (NICE) recommends that women at above-population-level risk of breast cancer (BC) are offered enhanced screening and risk-reducing interventions. Identification of these women largely relies on referral through primary care based on family history criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We compared the performance of the NICE criteria with versions of the BOADICEA multifactorial risk model in identifying women who developed BC within 10 years. Analyses included 1258 women aged under 50 years with family history, reproductive, lifestyle and polygenic risk data recruited to the Generations Study between 2004 and 2011 (392 BC cases), weighted to represent the UK population with respect to age and family history of BC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>NICE criteria identified 4.4% of women who developed BC within 10 years amongst 1.4% of women who met referral criteria. The full BOADICEA model identified up to 35% of women who developed BC, but with lower specificity and 26.5% of women meeting referral criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>NICE family history-based criteria applied to women under 50 miss most BCs occurring within 10 years. Multifactorial risk assessment in primary care could substantially improve the identification of women at risk who could be offered interventions before being invited to population-based screening.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-026-03547-2","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T01:01:28Z","timestamp":1785805288000},"page":"1452-1462","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of NICE criteria with the BOADICEA multifactorial risk model to guide breast cancer risk assessment and referral amongst women under age 50 within primary care"],"prefix":"10.1038","volume":"135","author":[{"given":"Reuben","family":"Frost","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0577-1571","authenticated-orcid":false,"given":"Lorenzo","family":"Ficorella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Berrington de Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonis C.","family":"Antoniou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Garc\u00eda-Closas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8501-2531","authenticated-orcid":false,"given":"Juliet A.","family":"Usher-Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"3547_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/CAAC.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/CAAC.21660.","journal-title":"CA Cancer J Clin"},{"key":"3547_CR2","unstructured":"National Institute for Health and Care Excellence. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. CG164. National Institute for Health and Care Excellence; 2017. https:\/\/www.nice.org.uk\/guidance\/cg164."},{"key":"3547_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/21501327211058322","volume":"13","author":"LJ Grimm","year":"2022","unstructured":"Grimm LJ, Avery CS, Hendrick E, Baker JA. Benefits and risks of mammography screening in women ages 40 to 49 years. J Prim Care Community Health. 2022;13:1\u20136. https:\/\/doi.org\/10.1177\/21501327211058322.","journal-title":"J Prim Care Community Health"},{"key":"3547_CR4","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1016\/S0140-6736(13)60140-3","volume":"381","author":"J Cuzick","year":"2013","unstructured":"Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet. 2013;381:1827\u201334. https:\/\/doi.org\/10.1016\/S0140-6736(13)60140-3.","journal-title":"Lancet"},{"key":"3547_CR5","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1059\/0003-4819-151-10-200911170-00147","volume":"151","author":"HD Nelson","year":"2009","unstructured":"Nelson HD, Fu R, Griffin JC, Nygren P, Smith B, Humphrey L. Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer. Ann Intern Med. 2009;151:703\u201315. https:\/\/doi.org\/10.1059\/0003-4819-151-10-200911170-00147.","journal-title":"Ann Intern Med"},{"key":"3547_CR6","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1093\/ije\/dyab036","volume":"50","author":"AN Hurson","year":"2021","unstructured":"Hurson AN, Pal Choudhury P, Gao C, H\u00fcsing A, Eriksson M, Shi M, et al. Prospective evaluation of a breast-cancer risk model integrating classical risk factors and polygenic risk in 15 cohorts from six countries. Int J Epidemiol. 2021;50:1897\u2013911. https:\/\/doi.org\/10.1093\/ije\/dyab036.","journal-title":"Int J Epidemiol"},{"key":"3547_CR7","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1038\/S41436-018-0406-9","volume":"21","author":"A Lee","year":"2019","unstructured":"Lee A, Mavaddat N, Wilcox AN, Cunningham AP, Carver T, Hartley S, et al. BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. Genet Med. 2019;21:1708\u201318. https:\/\/doi.org\/10.1038\/S41436-018-0406-9.","journal-title":"Genet Med"},{"key":"3547_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-022-02334-z","volume":"20","author":"PJ Ho","year":"2022","unstructured":"Ho PJ, Ho WK, Khng AJ, Yeoh YS, Tan BKT, Tan EY, et al. Overlap of high-risk individuals predicted by family history, and genetic and non-genetic breast cancer risk prediction models: implications for risk stratification. BMC Med. 2022;20:1\u201311. https:\/\/doi.org\/10.1186\/s12916-022-02334-z.","journal-title":"BMC Med"},{"key":"3547_CR9","doi-asserted-by":"publisher","unstructured":"Yang X, Eriksson M, Czene K, Lee A, Leslie G, Luch M, et al. Prospective validation of the BOADICEA multifactorial breast cancer risk prediction model in a large prospective study. J Med Genet. 2022;1\u201310. https:\/\/doi.org\/10.1136\/jmg-2022-108806.","DOI":"10.1136\/jmg-2022-108806"},{"key":"3547_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s44276-023-00027-5","volume":"2","author":"JA Usher-Smith","year":"2024","unstructured":"Usher-Smith JA, Tooth G, Follows A, Badran AR, Youngs A, Forman A, et al. Patterns of referrals to regional clinical genetics services for women potentially at above-population level risk of breast cancer. BJC Rep. 2024;2:1\u20137. https:\/\/doi.org\/10.1038\/s44276-023-00027-5.","journal-title":"BJC Rep"},{"key":"3547_CR11","doi-asserted-by":"publisher","unstructured":"Usher-Smith JA, Hindmarch S, French DP, Tischkowitz M, Moorthie S, Walter FM, et al. Proactive breast cancer risk assessment in primary care: a review based on the principles of screening. Br J Cancer. 2023. https:\/\/doi.org\/10.1038\/s41416-023-02145-w.","DOI":"10.1038\/s41416-023-02145-w"},{"key":"3547_CR12","doi-asserted-by":"publisher","unstructured":"Walker MJ, Blackmore KM, Chang A, Lambert-C\u00f4t\u00e9 L, Turgeon A, Antoniou AC, et al. Implementing multifactorial risk assessment with polygenic risk scores for personalized breast cancer screening in the population setting: challenges and opportunities. Cancers. 2024;16. https:\/\/doi.org\/10.3390\/cancers16112116.","DOI":"10.3390\/cancers16112116"},{"key":"3547_CR13","doi-asserted-by":"publisher","unstructured":"Walker MJ, Neely A, Antoniou AC, Broeders MJM, Brooks JD, Carver T, et al. Barriers and facilitators to delivering multifactorial risk assessment and communication for personalized breast cancer screening: a qualitative study exploring implementation in Canada. Curr Oncol. 2025;32. https:\/\/doi.org\/10.3390\/curroncol32030155.","DOI":"10.3390\/curroncol32030155"},{"key":"3547_CR14","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/BJC.2011.337","volume":"105","author":"AJ Swerdlow","year":"2011","unstructured":"Swerdlow AJ, Jones ME, Schoemaker MJ, Hemming J, Thomas D, Williamson J, et al. The Breakthrough Generations Study: design of a long-term UK cohort study to investigate breast cancer aetiology. Br J Cancer. 2011;105:911\u20137. https:\/\/doi.org\/10.1038\/BJC.2011.337.","journal-title":"Br J Cancer"},{"key":"3547_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ajhg.2018.11.002","volume":"104","author":"N Mavaddat","year":"2019","unstructured":"Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A, et al. Polygenic risk scores for prediction of breast cancer and breast cancer subtypes. Am J Hum Genet. 2019;104:21\u201334. https:\/\/doi.org\/10.1016\/j.ajhg.2018.11.002.","journal-title":"Am J Hum Genet"},{"key":"3547_CR16","doi-asserted-by":"publisher","first-page":"4232","DOI":"10.1002\/CNCR.34365","volume":"128","author":"DD Durham","year":"2022","unstructured":"Durham DD, Abraham LA, Roberts MC, Khan CP, Smith RA, Kerlikowske K, et al. Breast cancer incidence among women with a family history of breast cancer by relative\u2019s age at diagnosis. Cancer. 2022;128:4232\u201340. https:\/\/doi.org\/10.1002\/CNCR.34365.","journal-title":"Cancer"},{"key":"3547_CR17","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1136\/JMEDGENET-2022-108471","volume":"59","author":"A Lee","year":"2022","unstructured":"Lee A, Mavaddat N, Cunningham A, Carver T, Ficorella L, Archer S, et al. Enhancing the BOADICEA cancer risk prediction model to incorporate new data on RAD51C, RAD51D, BARD1 updates to tumour pathology and cancer incidence. J Med Genet. 2022;59:1206\u201318. https:\/\/doi.org\/10.1136\/JMEDGENET-2022-108471.","journal-title":"J Med Genet"},{"key":"3547_CR18","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1038\/SJ.BJC.6604305","volume":"98","author":"AC Antoniou","year":"2008","unstructured":"Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F, Narod SA, et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer. 2008;98:1457\u201366. https:\/\/doi.org\/10.1038\/SJ.BJC.6604305.","journal-title":"Br J Cancer"},{"key":"3547_CR19","doi-asserted-by":"publisher","unstructured":"Choudhury PP, Maas P, Wilcox A, Wheeler W, Brook M, Check D, et al. iCARE: an R package to build, validate and apply absolute risk models. PLoS ONE. 2020;15. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0228198.","DOI":"10.1371\/JOURNAL.PONE.0228198"},{"key":"3547_CR20","unstructured":"Breast cancer incidence (invasive) statistics | Cancer Research UK. [cited 2025 Nov 21]. Available from: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/breast-cancer\/incidence-invasive."},{"key":"3547_CR21","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1158\/1940-6207.CAPR-14-0037","volume":"7","author":"DG Evans","year":"2014","unstructured":"Evans DG, Brentnall AR, Harvie M, Dawe S, Sergeant JC, Stavrinos P, et al. Breast cancer risk in young women in the national breast screening programme: implications for applying NICE guidelines for additional screening and chemoprevention. Cancer Prev Res. 2014;7:993\u20131001. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-14-0037.","journal-title":"Cancer Prev Res"},{"key":"3547_CR22","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1093\/jnci\/djae335","volume":"117","author":"C Petitjean","year":"2025","unstructured":"Petitjean C, Wilcox N, Ficorella L, Dennis J, Tyrer J, Lush M, et al. Evaluating the performance of the Breast and Ovarian Analysis of Disease Incidence Algorithm model in predicting 10-year breast cancer risks in UK Biobank. J Natl Cancer Inst. 2025;117:948\u201358. https:\/\/doi.org\/10.1093\/jnci\/djae335.","journal-title":"J Natl Cancer Inst"},{"key":"3547_CR23","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/S1470-2045(18)30902-1","volume":"20","author":"MB Terry","year":"2019","unstructured":"Terry MB, Liao Y, Whittemore AS, Leoce N, Buchsbaum R, Zeinomar N, et al. 10-year performance of four models of breast cancer risk: a validation study. Lancet Oncol. 2019;20:504\u201317. https:\/\/doi.org\/10.1016\/S1470-2045(18)30902-1.","journal-title":"Lancet Oncol"},{"key":"3547_CR24","doi-asserted-by":"publisher","first-page":"844.","DOI":"10.1038\/S41416-025-03117-Y","volume":"133","author":"L Ficorella","year":"2025","unstructured":"Ficorella L, Yang X, Mavaddat N, Carver T, Hassan H, Dennis J, et al. Adapting the BOADICEA breast and ovarian cancer risk models for the ethnically diverse UK population. Br J Cancer. 2025;133:844. https:\/\/doi.org\/10.1038\/S41416-025-03117-Y.","journal-title":"Br J Cancer"},{"key":"3547_CR25","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1177\/0969141319877669","volume":"27","author":"A Ghanouni","year":"2020","unstructured":"Ghanouni A, Waller J, Stoffel ST, Vlaev I, von Wagner C. Acceptability of risk-stratified breast screening: effect of the order of presenting risk and benefit information. J Med Screen. 2020;27:52\u20136. https:\/\/doi.org\/10.1177\/0969141319877669.","journal-title":"J Med Screen"},{"key":"3547_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jpm11020095","volume":"11","author":"C Mbuya-Bienge","year":"2021","unstructured":"Mbuya-Bienge C, Pashayan N, Brooks JD, Dorval M, Chiquette J, Eloy L, et al. Women\u2019s views on multifactorial breast cancer risk assessment and risk-stratified screening: a population-based survey from four Provinces in Canada. J Pers Med. 2021;11:1\u201317. https:\/\/doi.org\/10.3390\/jpm11020095.","journal-title":"J Pers Med"},{"key":"3547_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-020-07464-2","volume":"20","author":"L Rainey","year":"2020","unstructured":"Rainey L, Van Der Waal D, Broeders MJM. Dutch women\u2019s intended participation in a risk-based breast cancer screening and prevention programme: a survey study identifying preferences, facilitators and barriers. BMC Cancer. 2020;20:1\u201314. https:\/\/doi.org\/10.1186\/s12885-020-07464-2.","journal-title":"BMC Cancer"},{"key":"3547_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3109\/0284186X.2015.1043024","volume":"55","author":"M Koitsalu","year":"2016","unstructured":"Koitsalu M, Sprangers MAG, Eklund M, Czene K, Hall P, Gr\u00f6nberg H, et al. Public interest in and acceptability of the prospect of risk-stratified screening for breast and prostate cancer. Acta Oncol. 2016;55:45\u201351. https:\/\/doi.org\/10.3109\/0284186X.2015.1043024.","journal-title":"Acta Oncol"},{"key":"3547_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-020-06959-2","volume":"20","author":"VG Woof","year":"2020","unstructured":"Woof VG, Ruane H, French DP, Ulph F, Qureshi N, Khan N, et al. The introduction of risk stratified screening into the NHS breast screening Programme: views from British-Pakistani women. BMC Cancer. 2020;20:1\u20139. https:\/\/doi.org\/10.1186\/s12885-020-06959-2.","journal-title":"BMC Cancer"},{"key":"3547_CR30","doi-asserted-by":"publisher","first-page":"992.","DOI":"10.3390\/jpm11100992","volume":"11","author":"MA Sierra","year":"2021","unstructured":"Sierra MA, Wheeler JCW, Devereux L, Trainer AH, Keogh L. Exploring implementation of personal breast cancer risk assessments. J Pers Med. 2021;11:992. https:\/\/doi.org\/10.3390\/jpm11100992.","journal-title":"J Pers Med"},{"key":"3547_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13225813","volume":"13","author":"C Kelley-jones","year":"2021","unstructured":"Kelley-jones C, Scott S, Waller J. Uk women\u2019s views of the concepts of personalised breast cancer risk assessment and risk-stratified breast screening: a qualitative interview study. Cancers. 2021;13:1\u201318. https:\/\/doi.org\/10.3390\/cancers13225813.","journal-title":"Cancers"},{"key":"3547_CR32","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1080\/0284186X.2018.1481291","volume":"57","author":"L Rainey","year":"2018","unstructured":"Rainey L, van der Waal D, Wengstr\u00f6m Y, Jervaeus A, Broeders MJM. Women\u2019s perceptions of the adoption of personalised risk-based breast cancer screening and primary prevention: a systematic review. Acta Oncol. 2018;57:1275\u201383. https:\/\/doi.org\/10.1080\/0284186X.2018.1481291.","journal-title":"Acta Oncol"},{"key":"3547_CR33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s10689-020-00188-z","volume":"20","author":"N Qureshi","year":"2021","unstructured":"Qureshi N, Dutton B, Weng S, Sheehan C, Chorley W, Robertson JFR, et al. Improving primary care identification of familial breast cancer risk using proactive invitation and decision support. Fam Cancer. 2021;20:13\u201321. https:\/\/doi.org\/10.1007\/s10689-020-00188-z.","journal-title":"Fam Cancer"},{"key":"3547_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2023.107786","volume":"177","author":"RA Dennison","year":"2023","unstructured":"Dennison RA, Thomas CV, Morris S, Usher-Smith JA. A discrete choice experiment to understand public preferences and priorities for risk-stratified bowel cancer screening programmes in the UK. Prev Med. 2023;177:107786. https:\/\/doi.org\/10.1016\/j.ypmed.2023.107786.","journal-title":"Prev Med"},{"key":"3547_CR35","doi-asserted-by":"publisher","unstructured":"Dennison RA, Taylor LC, Morris S, Boscott RA, Harrison H, Moorthie SA, et al. Public preferences for determining eligibility within stratified screening programmes: a discrete choice experiment. Med Decis Mak. 2023;1\u201313. https:\/\/doi.org\/10.1177\/0272989X231155790.","DOI":"10.1177\/0272989X231155790"},{"key":"3547_CR36","doi-asserted-by":"publisher","first-page":"e0336902.","DOI":"10.1371\/journal.pone.0336902","volume":"20","author":"F Stutzin Donoso","year":"2025","unstructured":"Stutzin Donoso F, Archer S, Walter FM, Morris S, Emery J, Broome J, et al. CanRisk-GP protocol: a feasibility study of incorporating proactive multifactorial breast cancer risk assessment into general practice. PLoS ONE. 2025;20:e0336902. https:\/\/doi.org\/10.1371\/journal.pone.0336902.","journal-title":"PLoS ONE"},{"key":"3547_CR37","doi-asserted-by":"publisher","unstructured":"Hindmarch S, Howell SJ, Usher-Smith JA, Horton R, Moukala-Mankassa D, Ng S, et al. Ethnic and socioeconomic disparities in participation in breast cancer risk assessment: findings from the BCAN-RAY study (NCT05305963). Front Cancer Control Soc. 2026;4. https:\/\/doi.org\/10.3389\/fcacs.2026.1759843.","DOI":"10.3389\/fcacs.2026.1759843"},{"key":"3547_CR38","doi-asserted-by":"publisher","first-page":"e078555.","DOI":"10.1136\/.bmjopen-2023-078555","volume":"14","author":"S Hindmarch","year":"2024","unstructured":"Hindmarch S, Howell SJ, Usher-Smith JA, Gorman L, Evans DG, French DP. The feasibility and acceptability of offering breast cancer risk assessment to general population women aged 30-39 years: a mixed-methods study protocol. BMJ Open. 2024;14:e078555. https:\/\/doi.org\/10.1136\/.bmjopen-2023-078555.","journal-title":"BMJ Open"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03547-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03547-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03547-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:57:27Z","timestamp":1792166247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03547-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,11,5]]}},"alternative-id":["3547"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03547-2","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"17 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ACA and LF are listed as creators of the BOADICEA v6 model, which has been licensed by Cambridge Enterprise (University of Cambridge). All other authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}